Author Archives: Shayna Korol

Efgartigimod as Injection Similar to Vyvgart in Treating gMG, Trial Finds

An under-the-skin injection formulation of efgartigimod is as effective as the therapy’s infusion version, sold as Vyvgart (efgartigimod alfa-fcab), at lowering immunoglobulin G antibody levels in people with generalized myasthenia gravis (gMG), according to top-line data from the ADAPT-SC trial. Based on these findings, Argenx, the therapy’s developer, plans…

Antibody Blood Tests May Help Monitor Long-term Clinical Status

Lower levels of antibodies targeting acetylcholine receptors in the bloodstream of people with myasthenia gravis (MG) were associated with improved clinical status, a study demonstrated. These findings showed not only that antibody blood tests are useful for diagnosing MG, but also that repetitive testing may be “valuable as a…

Japan Approves Vyvgart for Adults With Refractory gMG

Japan has approved Vyvgart (efgartigimod) to treat adults with generalized myasthenia gravis (gMG), the therapy’s developer, Argenx, announced. Vyvgart will be available to generalized MG patients, regardless of antibody status, who are refractory, which means they have failed to respond to steroids or nonsteroidal immunosuppressive therapies. The…

Immunovant to Launch US Phase 3 Trial for Batoclimab in MG

Immunovant is moving forward with its Phase 3 clinical trial in the U.S. to evaluate the investigational myasthenia gravis (MG) therapy batoclimab in the first half of this year. The announcement came after the company reached an agreement with the division of neurology within the U.S. Food…

Woman Diagnosed Postpartum With MG, Autoimmune Liver Disease

A 31-year-old woman was diagnosed with two autoimmune conditions — myasthenia gravis (MG) and a liver disease called primary biliary cirrhosis — after giving birth, a recent case study reported. “Given the fluctuation of the immune status during the postpartum period, combined autoimmune diseases need to be taken into…

Circular RNA Implicated in MG, Study Suggests

Altered production of circular RNA impaired the process of muscle cell growth and regeneration in people with myasthenia gravis (MG), a study has suggested. More studies investigating the role of circular RNA in MG may identify new molecular markers to monitor disease progression and reveal therapeutic targets, the researchers…

Immunosuppressants May Reduce Risk of Ocular MG Progressing to gMG

Treatment with immunosuppressant medications can delay disease progression in patients with ocular myasthenia gravis, which affects only eye muscles, to a more generalized form in which other muscles are affected, a study has found. The findings also showed that thymus gland abnormalities, as well as irregular results on facial…

2021 Myasthenia Gravis Survey Results

BioNews Survey Infographic

Myasthenia Gravis News conducted a survey from Feb. 11-March 28 to gain greater insight into the characteristics of the MG community and disease management. Results of the survey have now been published. Click on the image to view the infographic, and click here to read the story.